NanoViricides' drug pipeline to be discussed at NanoBusiness2009

Sep 8 2009NewsGuard 100/100 Score

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been asked to present a talk at NanoBusiness2009 - the 8th annual NanoBusiness Conference.

Dr. Diwan will speak about the nanoviricides™ drug pipeline, including Influenza (FluCide™), HIV (HIVCide™), antiviral eye-drops (EKCCide™) and the newly initiated Herpes “cold sores” and genital herpes preclinical stage program. He will speak about how the nanoviricides technology platform has enabled rapid drug development against a number of diseases caused by many different viruses. Dr. Diwan will speak in the session entitled “New Pharmaceutical Compounds Based on Soft Nanotechnology: Novel Classes of Therapeutics” on Wednesday, September 9. The Conference is being held at the McCormick Place, Chicago, IL.

http://www.nanoviricides.com/

Posted in: Medical Science News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Evaluating the efficacy of harmol in treating herpes simplex virus-induced keratitis
Long-term antiviral treatment may protect vision from shingles
Recombinant shingles vaccination found to lower dementia risk
Unraveling the mystery of viral evolution
New insights into pain mechanisms related to viral infections
Recombinant shingles vaccine linked to lower dementia risk, especially in women
Rising syphilis cases highlight gaps in public knowledge on symptoms and treatment
APOE ε4 carrier status increases the long-term cognitive decline risk associated with herpes zoster

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
First global estimates of economic costs of genital herpes infections